Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease

被引：13

作者：

Grootendorst, Diana C. ^{[1
]}

Rabe, Klaus F. ^{[1
]}

机构：

[1] Leiden Univ, Dept Pulmonol, Med Ctr, C2-P,POB 9600, NL-2300 RC Leiden, Netherlands

来源：

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY | 2002年 / 2卷 / 01期

关键词：

D O I：

10.1097/00130832-200202000-00010

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Phosphodiesterase type 4 plays an important role in modulating the activity of cells that are involved in the inflammatory processes occurring in chronic obstructive pulmonary disease and asthma. During the past decade, interest has focused on the development of selective inhibitors of phosphodiesterase-4, in an attempt to generate new treatment modalities that control airway inflammation not only in patients with asthma but also in those with chronic obstructive pulmonary disease. The aim of the present review is to discuss the results of recent clinical intervention studies with phosphodiesterase-4 inhibitors in patients with asthma or chronic obstructive pulmonary disease. (C) 2002 Lippincott Williams & Wilkin.

引用

页码：61 / 67

页数：7

共 45 条

[1]

Altose MD, 2000, NEW ENGL J MED, V343, P1902

[2] THEOPHYLLINE PHARMACOKINETICS AND LIVER-FUNCTION INDEXES IN CHRONIC LIVER-DISEASE [J].

AMODIO, P ;

LAURO, S ;

RONDANA, M ;

CREMA, G ;

MERKEL, C ;

GATTA, A ;

RUOL, A .

RESPIRATION, 1991, 58 (02) :106-111

[3]

[Anonymous], 2001, AM J RESP CRIT CARE

[4]

[Anonymous], 1998, NIH PUBL

[5]

[Anonymous], 2001, AM J RESP CRIT CARE

[6]

Aoki M, 2001, J PHARMACOL EXP THER, V298, P1142

[7]

Bagchi I, 2001, AM J RESP CRIT CARE, V163, pA507

[8]

Bethke T, 2001, EUR RESP J S33, V18, p156s

[9]

Bethke TD, 2001, AM J RESP CRIT CAR S, V163, pA431

[10]

Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280

← 1 2 3 4 5 →